Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Cash & Equivalents (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Equivalents history spans 7 years, with the latest figure at $298.5 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 9.91% to $298.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $298.5 million through Mar 2026, up 9.91% year-over-year, with the annual reading at $334.5 million for FY2025, 85.4% up from the prior year.
  • Cash & Equivalents came in at $298.5 million for Q1 2026, down from $334.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $501.8 million in Q2 2023 to a low of $23336.0 in Q1 2022.
  • The 5-year median for Cash & Equivalents is $312.4 million (2023), against an average of $270.1 million.
  • Year-over-year, Cash & Equivalents crashed 98.01% in 2022 and then soared 214714.87% in 2023.
  • MoonLake Immunotherapeutics' Cash & Equivalents stood at $39.5 million in 2022, then skyrocketed by 1042.04% to $451.2 million in 2023, then crashed by 60.01% to $180.4 million in 2024, then surged by 85.4% to $334.5 million in 2025, then decreased by 10.77% to $298.5 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Cash & Equivalents are $298.5 million (Q1 2026), $334.5 million (Q4 2025), and $350.7 million (Q3 2025).